



NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

REGULATED INFORMATION FOR IMMEDIATE RELEASE

AB SCIENCE ANNOUNCES THE SUCCESS OF A PRIVATE PLACEMENT

- ***EUR 19.00 million raised through a private placement of 1,241,831 new ordinary shares at a price of EUR 15.30 by way of an accelerated book-building.***
- ***Securities subscribed by American and European qualified investors.***
- ***The Company has enough cash to finance its operations until end 2019.***

Paris, France – March 31, 2017

AB Science S.A. (the « **Company** » or « **AB Science** »), NYSE Euronext – FR0010557264 - AB), a pharmaceutical company specialized in research, development and commercialization of protein kinase inhibitors (PKIs) announces today the completion of a private placement of new ordinary shares that resulted in gross proceeds for the Company of approximately EUR 19.00 million by accelerated book-building procedure completed on March 30, 2017 after the market closed.

The private placement was managed by Chardan as Bookrunner and Sole Placement Agent.

Terms of the private placement

The private placement was subscribed by American and European collective investment funds investing in the pharmaceutical or biotechnological sector (including AB Science's existing shareholders) and a total of 1,241,831 new ordinary shares are to be issued (through a capital increase without shareholders' preemption rights), representing approximately 3.10% of the outstanding shares prior to the private placement and a dilution of approximately 3.00% for existing shareholders. On a fully diluted basis, the dilution would be approximately 2.23%.

Following an accelerated book-building process, the price of the placement was set at EUR 15.30 per new ordinary share. This price represents a 10% discount to the closing stock price on March 30, 2017, *i.e.* EUR 17.01 and a 9.68% discount to the volume weighted average price of the last five trading days preceding the pricing date, *i.e.* EUR 16.94.

The net proceeds to AB Science are estimated to be approximately EUR 18.43 million.

Use of proceeds

AB Science intends to primarily use the net proceeds from the placement to fund the Company's general needs and finance its clinical development program.

Settlement and listing of the new shares

The settlement of the new ordinary shares is expected to take place on April 4, 2017. The settlement is subject to customary closing conditions. The new ordinary shares are expected to be admitted to trade on the regulated market of Euronext Paris under the existing ISIN securities identification code for AB Science's ordinary shares on April 4, 2017. The new ordinary shares, with a par value of EUR 0.01, will be fungible in all respects with AB Science existing ordinary shares.

The private placement is not the subject of a prospectus to be approved by the French market regulator ("AMF") or any other regulatory authority.

The private placement was conducted in accordance with Article L. 411-2 II of the French Monetary and Financial Code pursuant to the first resolution of the extraordinary shareholders meeting held on December 9, 2016.

Public Information

Additional information on AB Science, including its business, financials, perspectives and risk factors on its business, activities, and securities can be found in the *document de référence*, filed with the AMF on November 22, 2016 under n° R. 16-078, available with other regulated information about the Company, at the Company's website (www.ab-science.com) and at the AMF's website (www.amf-france.org).

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe. The company is currently pursuing thirteen phase 3 studies in human medicine in metastatic prostate cancer, metastatic pancreatic cancer, relapsing metastatic colorectal cancer, relapsing metastatic ovarian cancer, GIST, metastatic melanoma expressing JM mutation of c-Kit, relapsing multiple myeloma, relapsing T-cell lymphoma, mastocytosis, severe asthma, amyotrophic lateral sclerosis, Alzheimer's disease and progressive forms of multiple sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the AMF, including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

Disclaimer

In France, the offer of AB Science shares described above will take place solely as a private placement, in accordance with Article L. 411-2 of the of the French Monetary and Financial

Code and applicable regulations. The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the French Monetary and Financial Code.

With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.

This press release and the information it contains does not, and will not, constitute a public offering to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, shares of AB Science in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended and applicable State securities laws. AB Science does not intend to register securities or conduct a public offering in the United States.

This distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

For additional information on AB Science, please contact:

AB SCIENCE

Financial communication and public relations
investors@ab-science.com